# Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/real-world-efficacy-and-safety-of-nivolumab-in-previously-treated-metastatic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group,Elena Verzoni,Giacomo Cartenì,Enrico Cortesi,Diana Giannarelli,Andrea De Giglio,Roberto Sabbatini,Sebastiano Buti,Sabrina Rossetti,Francesco Cognetti,Francesca Rastelli,Alberto F. Sobrero,D. Turci,Cora N. Sternberg,Camillo Porta,Federico Cappuzzo,Giampaolo Tortora,Davide Tassinari,Stefano Panni,Antonio Pazzola,Gianmarco Surico,Alessandra Raimondi,Ugo De Giorgi,Giuseppe Procopio |
| Citations | 140 |
| DOI | 10.1186/s40425-019-0579-z |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://jitc.bmj.com/content/jitc/7/1/99.full.pdf |
| OpenAlex ID | https://openalex.org/W2942674623 |
| PMID | 30944023 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Sebastiano Buti](https://scholariq.org/researchers/sebastiano-buti/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.